

Deciphering Distinct Genetic Risk Factors for FTL D-TDP Pathological Subtypes via Whole-Genome Sequencing

Cyril Pottier^{1,2,3,4,5,*}, Fahri Küçükali^{2,3}, Matt Baker¹, Anthony Batzler⁶, Gregory D. Jenkins⁶, Marka van Blitterswijk¹, Cristina T. Vicente^{2,3}, Wouter De Coster^{2,3}, Sarah Wynants^{2,3}, Pieter Van de Walle^{2,3}, Owen A. Ross¹, Melissa E. Murray¹, Júlia Faura^{2,3}, Stephen J. Haggarty⁷, Jeroen GJ. van Rooij⁸, Merel O. Mol⁸, Ging-Yuek R. Hsiung⁹, Caroline Graff^{10,11}, Linn Öijerstedt^{10,11}, Manuela Neumann^{12,13}, Yan Asmann¹⁴, Shannon K. McDonnell⁶, Saurabh Baheti⁶, Keith A. Josephs¹⁵, Jennifer L. Whitwell¹⁶, Kevin F. Bieniek^{1,17}, Leah Forsberg¹⁵, Hilary Heuer¹⁸, Argentina Lario Lago¹⁸, Ethan G. Geier¹⁸, Jennifer S. Yokoyama¹⁸, Alexis P. Oddi¹⁸, Margaret Flanagan¹⁷, Qinwen Mao¹⁹, John R. Hodges²⁰, John B. Kwok^{21,22}, Kimiko Domoto-Reilly²³, Matthis Synofzik^{12,24}, Carlo Wilke^{12,24}, Chiadi Onyike²⁵, Bradford C. Dickerson²⁶, Bret M. Evers²⁷, Brittany N. Dugger²⁸, David G. Munoz^{29,30}, Julia Keith^{30,31}, Lorne Zinman³¹, Ekaterina Rogaeva³², EunRan Suh³³, Tamar Gefen³⁴, Changiz Geula³⁴, Sandra Weintraub³⁴, Janine Diehl-Schmid^{35,36}, Martin R. Farlow³⁷, Dieter Edbauer³⁸, Bryan K. Woodruff³⁹, Richard J. Caselli³⁹, Laura L. Donker Kaat⁴⁰, Edward D. Huey⁴¹, Eric M. Reiman⁴², Simon Mead⁴³, Andrew King^{44,45}, Sigrun Roeber⁴⁶, Alissa L. Nana¹⁸, Nilufer Ertekin-Taner^{1,47}, David S. Knopman¹⁵, Ronald C. Petersen¹⁵, Leonard Petrucelli¹, Ryan J. Uitti⁴⁷, Zbigniew K. Wszolek⁴⁷, Eliana Marisa Ramos⁴⁸, Lea T. Grinberg¹⁸, Maria Luisa Gorno Tempini¹⁸, Howard J. Rosen⁴⁹, Salvatore Spina¹⁸, Olivier Piguet⁵⁰, Murray Grossman⁵¹, John Q. Trojanowski³³, Dirk C. Keene⁵², Jin Lee-Way⁵³, Johannes Prudlo^{54,55}, Daniel H. Geschwind⁴⁸, Robert A. Rissman⁵⁶, Carlos Cruchaga⁵⁷, Bernardino Ghetti⁵⁸, Glenda M. Halliday²¹, Thomas G. Beach⁵⁹, Geidy E. Serrano⁵⁹, Thomas Arzberger^{46,60}, Jochen Herms^{38,46}, Adam L. Boxer¹⁸, Lawrence S. Honig⁶¹, Jean P. Vonsattel⁶², Oscar L. Lopez⁶³, Julia Kofler⁶⁴, Charles L. White III²⁷, Marla Gearing⁶⁵, Jonathan Glass⁶⁵, Jonathan D. Rohrer⁶⁶, David J. Irwin⁵¹, Edward B. Lee³³, Vivianne Van Deerlin³³, Rudolph Castellani⁶⁷, Marsel M. Mesulam³⁴, Maria C. Tartaglia³², Elizabeth C. Finger⁶⁸, Claire Troakes⁴⁴, Safa Al-Sarraj^{44,69}, Bruce L. Miller¹⁸, Harro Seelaar⁸, Neill R. Graff-Radford⁴⁷, Bradley F. Boeve¹⁵, Ian RA. Mackenzie⁷⁰, John C. van Swieten⁸, William W. Seeley¹⁸, Kristel Slegers^{2,2}, Dennis W. Dickson¹, Joanna M. Biernacka^{6,71}, Rosa Rademakers^{1,2,3,*}

† In memoriam

* Corresponding Authors

Rosa Rademakers, Ph.D. (ORCID: 0000-0002-4049-0863)

VIB Center for Molecular Neurology

Universiteitsplein 1, 2610 Wilrijk, Belgium

Phone: +32 3 265 95 95

E-mail: rosa.rademakers@uantwerpen.vib.be

Cyril Pottier, Ph.D.

Department of Neurology, Washington University School of Medicine

St Louis, MO, United States of America

Phone: +1 314 747 2601

E-mail: cpottier@wustl.edu

¹Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, United States of America

²Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium

³VIB Center for Molecular Neurology, VIB, Antwerp, Belgium

⁴Department of Neurology, Washington University School of Medicine, St Louis, MO, United States of America

⁵NeuroGenomics and Informatics Center, Washington University School of Medicine, St Louis, MO, United States of America

⁶Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 55905, United States of America

⁷Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, United States of America

⁸Department of Neurology, Erasmus Medical Center, Wytemaweg 80, Rotterdam, 3015 CN, The Netherlands

⁹Department of Medicine, Division of Neurology, University of British Columbia, Vancouver, BC, V6T 2B5, Canada

¹⁰Division of Neurogeriatrics, Karolinska Institutet, Bioclinicum J10:20, Visionsgatan 4, Solna, 171 64, Sweden

¹¹Unit for Hereditary Dementias, Karolinska University Hospital, Solna, 171 64, Sweden

¹²German Center for Neurodegenerative Diseases (DZNE), Tübingen, 72076, Germany

- ¹³Department of Neuropathology, University of Tübingen, Tübingen, 72076, Germany
- ¹⁴Department of Health Sciences Research, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, United States of America
- ¹⁵Department of Neurology, Mayo Clinic, Rochester, MN, 55905, United States of America
- ¹⁶Department of Radiology, Mayo Clinic, Rochester, MN, 55905, United States of America
- ¹⁷University of Texas Health Science Center San Antonio, San Antonio, TX, 78229, United States of America
- ¹⁸Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, 94158, United States of America
- ¹⁹Department of Pathology, University of Utah, Salt Lake City, UT, 84112, United States of America
- ²⁰Central Clinical School and Brain and Mind Centre, University of Sydney, Sydney, 2050, Australia
- ²¹University of Sydney, Sydney, 2050, Australia
- ²²NeuRA, University of New South Wales, Randwick, 2031, Australia
- ²³Department of Neurology, University of Washington, 325 9th Ave, Seattle, WA, 98104, United States of America
- ²⁴Division Translational Genomics of Neurodegenerative Diseases, Center for Neurology and Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
- ²⁵Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, 21218, United States of America
- ²⁶Department of Neurology, Case Western Reserve University, Cleveland, OH, 44106, United States of America
- ²⁷Division of Neuropathology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9073, United States of America
- ²⁸Department of Pathology and Laboratory Medicine, University of California, Davis Medical Center, Sacramento, CA, 95817, United States of America
- ²⁹St. Michael's Hospital, 30 Bond St, Toronto, ON, M5B 1W8, Canada
- ³⁰Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, M5S 1A1, Canada
- ³¹Sunnybrook Health Sciences Centre, Toronto, ON, M4N 3M5, Canada
- ³²Krembil Discovery Tower, Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, 60 Leonard Av, Toronto, ON, M5T 0S8, Canada
- ³³Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research,

Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, United States of America

³⁴Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University, Chicago, IL, 60611, United States of America

³⁵Department of Psychiatry and Psychotherapy, Technical University of Munich, Munich, 80333, Germany

³⁶kbo-Inn-Salzach-Klinikum, Clinical Center for Psychiatry, Psychotherapy, Psychosomatic Medicine, Geriatrics and Neurology, Wasserburg/Inn, 83512, Germany

³⁷Department of Neurology, Indiana University School of Medicine, 355 West 16th Street, Indianapolis, IN, 46202, United States of America

³⁸German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen-Str 17, Munich, 81377, Germany

³⁹Department of Neurology, Mayo Clinic, Scottsdale, AZ, 85259, United States of America

⁴⁰Department of Clinical Genetics, Erasmus Medical Center, Wytemaweg 80, Rotterdam, 3015 CN, The Netherlands

⁴¹Department of Psychiatry and Human Behavior, Brown Alpert Medical School, Brown University, Providence, RI, 02912, United States of America

⁴²Banner Alzheimer's Institute, Phoenix, AZ, 85006, United States of America

⁴³MRC Prion Unit at University College London, Institute of Prion Diseases, London, United Kingdom

⁴⁴Department of Basic and Clinical Neuroscience, London Neurodegenerative Diseases Brain Bank, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 8AF, United Kingdom

⁴⁵Department of Clinical Neuropathology, King's College Hospital NHS Foundation Trust, London, SE5 9RS, United Kingdom

⁴⁶Centre for Neuropathology and Prion Research, Ludwig-Maximilians-University of Munich, Feodor-Lynen-Straße 23, Munich, 81377, Germany

⁴⁷Department of Neurology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, United States of America

⁴⁸Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, 90095, United States of America

⁴⁹Department of Pathology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, 94158, United States of America

- ⁵⁰School of Psychology and Brain and Mind Centre, University of Sydney, Sydney, 2050, Australia
- ⁵¹Department of Neurology, Penn Frontotemporal Degeneration Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, United States of America
- ⁵²University of Washington BioRepository and Integrated Neuropathology (BRaIN) lab, Harborview Medical Center, 325 9th Ave, Seattle, WA, 98104, United States of America
- ⁵³M.I.N.D. Institute Laboratory, University of California, Davis Medical Center, 2805 50th St, Sacramento, CA, 95817, United States of America
- ⁵⁴German Center for Neurodegenerative Diseases (DZNE), Rostock, 18147, Germany
- ⁵⁵Department of Neurology, Rostock University Medical Center, Rostock, 18147, Germany
- ⁵⁶Alzheimer's Therapeutic Research Institute, Keck School of Medicine of the University of Southern California, San Diego, CA, USA
- ⁵⁷Department of Psychiatry, Knight Alzheimer Disease Research Center, Washington University School of Medicine, Saint Louis, MO, 63108, United States of America
- ⁵⁸Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, 635 Barnhill Drive, Indianapolis, IN, 46202, United States of America
- ⁵⁹Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, AZ, 85351, United States of America
- ⁶⁰Department of Psychiatry and Psychotherapy, University Hospital, Ludwig-Maximilians-University of Munich, Munich, 81377, Germany
- ⁶¹Department of Neurology, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, 630 West 168th St, New York, NY, 10032, United States of America
- ⁶²Department of Pathology, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, 630 West 168th St, New York, NY, 10032, United States of America
- ⁶³Department of Neurology, University of Pittsburgh, Pittsburgh, PA, 15213, United States of America
- ⁶⁴Department of Pathology, University of Pittsburgh, Pittsburgh, PA, 15213, United States of America
- ⁶⁵Department of Pathology and Laboratory Medicine and Department of Neurology, Emory University, Atlanta, GA, 30322, United States of America
- ⁶⁶Department of Neurodegenerative Disease, Dementia Research Centre, University College London Queen Square Institute of Neurology, London, WC1N 3BG, United Kingdom
- ⁶⁷Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611,

United States of America

⁶⁸Department of Clinical Neurological Sciences, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, N6A 2E2, Canada

⁶⁹King's College Hospital NHS Foundation Trust, London, SE5 9RS, United Kingdom

⁷⁰Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, V6T 1Z7, Canada

⁷¹Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, 55905, United States of America

SUPPLEMENTARY NOTES

ADSP Acknowledgment:

The Alzheimer's Disease Sequencing Project (ADSP) is comprised of two Alzheimer's Disease (AD) genetics consortia and three National Human Genome Research Institute (NHGRI) funded Large Scale Sequencing and Analysis Centers (LSAC). The two AD genetics consortia are the Alzheimer's Disease Genetics Consortium (ADGC) funded by NIA (U01 AG032984), and the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) funded by NIA (R01 AG033193), the National Heart, Lung, and Blood Institute (NHLBI), other National Institute of Health (NIH) institutes and other foreign governmental and non-governmental organizations. The Discovery Phase analysis of sequence data is supported through U01AG047133 (to Drs. Schellenberg, Farrer, Pericak-Vance, Mayeux, and Haines); U01AG049505 to Dr. Seshadri; U01AG049506 to Dr. Boerwinkle; U01AG049507 to Dr. Wijmsman; and U01AG049508 to Dr. Goate and the Discovery Extension Phase analysis is supported through U01AG052411 to Dr. Goate, U01AG052410 to Dr. Pericak-Vance and U01AG052409 to Drs. Seshadri and Fornage.

Sequencing for the Follow Up Study (FUS) is supported through U01AG057659 (to Drs. PericakVance, Mayeux, and Vardarajan) and U01AG062943 (to Drs. Pericak-Vance and Mayeux). Data generation and harmonization in the Follow-up Phase is supported by U54AG052427 (to Drs. Schellenberg and Wang). The FUS Phase analysis of sequence data is supported through U01AG058589 (to Drs. Destefano, Boerwinkle, De Jager, Fornage, Seshadri,

and Wijsman), U01AG058654 (to Drs. Haines, Bush, Farrer, Martin, and Pericak-Vance), U01AG058635 (to Dr. Goate), RF1AG058066 (to Drs. Haines, Pericak-Vance, and Scott), RF1AG057519 (to Drs. Farrer and Jun), R01AG048927 (to Dr. Farrer), and RF1AG054074 (to Drs. Pericak-Vance and Beecham).

The ADGC cohorts include: Adult Changes in Thought (ACT) (U01 AG006781, U19 AG066567), the Alzheimer's Disease Research Centers (ADRC) (P30 AG062429, P30 AG066468, P30 AG062421, P30 AG066509, P30 AG066514, P30 AG066530, P30 AG066507, P30 AG066444, P30 AG066518, P30 AG066512, P30 AG066462, P30 AG072979, P30 AG072972, P30 AG072976, P30 AG072975, P30 AG072978, P30 AG072977, P30 AG066519, P30 AG062677, P30 AG079280, P30 AG062422, P30 AG066511, P30 AG072946, P30 AG062715, P30 AG072973, P30 AG066506, P30 AG066508, P30 AG066515, P30 AG072947, P30 AG072931, P30 AG066546, P20 AG068024, P20 AG068053, P20 AG068077, P20 AG068082, P30 AG072958, P30 AG072959), the Chicago Health and Aging Project (CHAP) (R01 AG11101, RC4 AG039085, K23 AG030944), Indiana Memory and Aging Study (IMAS) (R01 AG019771), Indianapolis Ibadan (R01 AG009956, P30 AG010133), the Memory and Aging Project (MAP) (R01 AG17917), Mayo Clinic (MAYO) (R01 AG032990, U01 AG046139, R01 NS080820, RF1 AG051504, P50 AG016574), Mayo Parkinson's Disease controls (NS039764, NS071674, 5RC2HG005605), University of Miami (R01 AG027944, R01 AG028786, R01 AG019085, IIRG09133827, A2011048), the Multi-Institutional Research in Alzheimer's Genetic Epidemiology Study (MIRAGE) (R01 AG09029, R01 AG025259), the National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD) (U24 AG021886), the National Institute on Aging Late Onset Alzheimer's Disease Family Study (NIA- LOAD) (U24 AG056270), the Religious Orders Study (ROS) (P30 AG10161, R01 AG15819), the Texas Alzheimer's Research and Care Consortium (TARCC) (funded by the Darrell K Royal Texas Alzheimer's Initiative), Vanderbilt University/Case Western Reserve University (VAN/CWRU) (R01 AG019757, R01 AG021547, R01 AG027944, R01 AG028786, P01 NS026630, and Alzheimer's Association), the Washington Heights-Inwood Columbia Aging Project (WHICAP) (RF1 AG054023), the University of Washington Families (VA Research Merit Grant, NIA: P50AG005136, R01AG041797, NINDS: R01NS069719), the Columbia University Hispanic Estudio Familiar de Influencia Genetica de Alzheimer (EFIGA) (RF1 AG015473), the University of Toronto (UT) (funded by Wellcome Trust, Medical

Research Council, Canadian Institutes of Health Research), and Genetic Differences (GD) (R01 AG007584). The CHARGE cohorts are supported in part by National Heart, Lung, and Blood Institute (NHLBI) infrastructure grant HL105756 (Psaty), RC2HL102419 (Boerwinkle) and the neurology working group is supported by the National Institute on Aging (NIA) R01 grant AG033193.

The CHARGE cohorts participating in the ADSP include the following: Austrian Stroke Prevention Study (ASPS), ASPS-Family study, and the Prospective Dementia Registry-Austria (ASPS/PRODEM-Aus), the Atherosclerosis Risk in Communities (ARIC) Study, the Cardiovascular Health Study (CHS), the Erasmus Rucphen Family Study (ERF), the Framingham Heart Study (FHS), and the Rotterdam Study (RS). ASPS is funded by the Austrian Science Fond (FWF) grant number P20545-P05 and P13180 and the Medical University of Graz. The ASPS-Fam is funded by the Austrian Science Fund (FWF) project I904), the EU Joint Programme – Neurodegenerative Disease Research (JPND) in frame of the BRIDGET project (Austria, Ministry of Science) and the Medical University of Graz and the Steiermärkische Krankenanstalten Gesellschaft. PRODEM-Austria is supported by the Austrian Research Promotion agency (FFG) (Project No. 827462) and by the Austrian National Bank (Anniversary Fund, project 15435. ARIC research is carried out as a collaborative study supported by NHLBI contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C). Neurocognitive data in ARIC is collected by U01 2U01HL096812, 2U01HL096814, 2U01HL096899, 2U01HL096902, 2U01HL096917 from the NIH (NHLBI, NINDS, NIA and NIDCD), and with previous brain MRI examinations funded by R01-HL70825 from the NHLBI. CHS research was supported by contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, and grants U01HL080295 and U01HL130114 from the NHLBI with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided by R01AG023629, R01AG15928, and R01AG20098 from the NIA. FHS research is supported by NHLBI contracts N01-HC-25195 and HHSN268201500001I. This study was also supported by additional grants from the NIA (R01s AG054076, AG049607 and AG033040 and NINDS (R01 NS017950). The ERF study as a part of EUROSPAN (European Special Populations Research

Network) was supported by European Commission FP6 STRP grant number 018947 (LSHG-CT-2006-01947) and also received funding from the European Community's Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F4- 2007-201413 by the European Commission under the programme "Quality of Life and Management of the Living Resources" of 5th Framework Programme (no. QLG2-CT-2002- 01254). High-throughput analysis of the ERF data was supported by a joint grant from the Netherlands Organization for Scientific Research and the Russian Foundation for Basic Research (NWO-RFBR 047.017.043). The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, the Netherlands Organization for Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the municipality of Rotterdam. Genetic data sets are also supported by the Netherlands Organization of Scientific Research NWO Investments (175.010.2005.011, 911-03-012), the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), and the Netherlands Genomics Initiative (NGI)/Netherlands Organization for Scientific Research (NWO) Netherlands Consortium for Healthy Aging (NCHA), project 050-060-810. All studies are grateful to their participants, faculty and staff. The content of these manuscripts is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the U.S. Department of Health and Human Services.

The FUS cohorts include: the Alzheimer's Disease Research Centers (ADRC) (P30 AG062429, P30 AG066468, P30 AG062421, P30 AG066509, P30 AG066514, P30 AG066530, P30 AG066507, P30 AG066444, P30 AG066518, P30 AG066512, P30 AG066462, P30 AG072979, P30 AG072972, P30 AG072976, P30 AG072975, P30 AG072978, P30 AG072977, P30 AG066519, P30 AG062677, P30 AG079280, P30 AG062422, P30 AG066511, P30 AG072946, P30 AG062715, P30 AG072973, P30 AG066506, P30 AG066508, P30 AG066515, P30 AG072947, P30 AG072931, P30 AG066546, P20 AG068024, P20 AG068053, P20 AG068077, P20 AG068082, P30 AG072958, P30 AG072959), Alzheimer's Disease Neuroimaging Initiative (ADNI) (U19AG024904), Amish Protective Variant Study (RF1AG058066), Cache County Study (R01AG11380, R01AG031272, R01AG21136, RF1AG054052), Case Western Reserve University Brain Bank (CWRUBB) (P50AG008012), Case Western Reserve University Rapid

Decline (CWRURD) (RF1AG058267, NU38CK000480), CubanAmerican Alzheimer's Disease Initiative (CuAADI) (3U01AG052410), Estudio Familiar de Influencia Genetica en Alzheimer (EFIGA) (5R37AG015473, RF1AG015473, R56AG051876), Genetic and Environmental Risk Factors for Alzheimer Disease Among African Americans Study (GenerAAtions) (2R01AG09029, R01AG025259, 2R01AG048927), Gwangju Alzheimer and Related Dementias Study (GARD) (U01AG062602), Hillblom Aging Network (2014-A-004-NET, R01AG032289, R01AG048234), Hussman Institute for Human Genomics Brain Bank (HIHGBB) (R01AG027944, Alzheimer's Association "Identification of Rare Variants in Alzheimer Disease"), Ibadan Study of Aging (IBADAN) (5R01AG009956), Longevity Genes Project (LGP) and LonGenity (R01AG042188, R01AG044829, R01AG046949, R01AG057909, R01AG061155, P30AG038072), Mexican Health and Aging Study (MHAS) (R01AG018016), Multi-Institutional Research in Alzheimer's Genetic Epidemiology (MIRAGE) (2R01AG09029, R01AG025259, 2R01AG048927), Northern Manhattan Study (NOMAS) (R01NS29993), Peru Alzheimer's Disease Initiative (PeADI) (RF1AG054074), Puerto Rican 1066 (PR1066) (Wellcome Trust (GR066133/GR080002), European Research Council (340755)), Puerto Rican Alzheimer Disease Initiative (PRADI) (RF1AG054074), Reasons for Geographic and Racial Differences in Stroke (REGARDS) (U01NS041588), Research in African American Alzheimer Disease Initiative (REAAADI) (U01AG052410), the Religious Orders Study (ROS) (P30 AG10161, P30 AG72975, R01 AG15819, R01 AG42210), the RUSH Memory and Aging Project (MAP) (R01 AG017917, R01 AG42210Stanford Extreme Phenotypes in AD (R01AG060747), University of Miami Brain Endowment Bank (MBB), University of Miami/Case Western/North Carolina A&T African American (UM/CASE/NCAT) (U01AG052410, R01AG028786), and Wisconsin Registry for Alzheimer's Prevention (WRAP) (R01AG027161 and R01AG054047).

The four LSACs are: the Human Genome Sequencing Center at the Baylor College of Medicine (U54 HG003273), the Broad Institute Genome Center (U54HG003067), The American Genome Center at the Uniformed Services University of the Health Sciences (U01AG057659), and the Washington University Genome Institute (U54HG003079). Genotyping and sequencing for the ADSP FUS is also conducted at John P. Hussman Institute for Human Genomics (HIHG) Center for Genome Technology (CGT).

Biological samples and associated phenotypic data used in primary data analyses were stored at Study Investigators institutions, and at the National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD, U24AG021886) at Indiana University funded by NIA. Associated Phenotypic Data used in primary and secondary data analyses were provided by Study Investigators, the NIA funded Alzheimer's Disease Centers (ADCs), and the National Alzheimer's Coordinating Center (NACC, U24AG072122) and the National Institute on Aging Genetics of Alzheimer's Disease Data Storage Site (NIAGADS, U24AG041689) at the University of Pennsylvania, funded by NIA. Harmonized phenotypes were provided by the ADSP Phenotype Harmonization Consortium (ADSP-PHC), funded by NIA (U24 AG074855, U01 AG068057 and R01 AG059716) and Ultrascale Machine Learning to Empower Discovery in Alzheimer's Disease Biobanks (AI4AD, U01 AG068057). This research was supported in part by the Intramural Research Program of the National Institutes of Health, National Library of Medicine. Contributors to the Genetic Analysis Data included Study Investigators on projects that were individually funded by NIA, and other NIH institutes, and by private U.S. organizations, or foreign governmental or nongovernmental organizations.

The ADSP Phenotype Harmonization Consortium (ADSP-PHC) is funded by NIA (U24 AG074855, U01 AG068057 and R01 AG059716). The harmonized cohorts within the ADSP-PHC include: the Anti-Amyloid Treatment in Asymptomatic Alzheimer's study (A4 Study), a secondary prevention trial in preclinical Alzheimer's disease, aiming to slow cognitive decline associated with brain amyloid accumulation in clinically normal older individuals. The A4 Study is funded by a public-private-philanthropic partnership, including funding from the National Institutes of Health-National Institute on Aging, Eli Lilly and Company, Alzheimer's Association, Accelerating Medicines Partnership, GHR Foundation, an anonymous foundation and additional private donors, with in-kind support from Avid and Cogstate. The companion observational Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) Study is funded by the Alzheimer's Association and GHR Foundation. The A4 and LEARN Studies are led by Dr. Reisa Sperling at Brigham and Women's Hospital, Harvard Medical School and Dr. Paul Aisen at the Alzheimer's Therapeutic Research Institute (ATRI), University of Southern California. The A4 and LEARN Studies are coordinated by ATRI at the University of Southern California, and the data are made available through the Laboratory for Neuro Imaging at the University of Southern California. The participants screening for the A4 Study provided

permission to share their de-identified data in order to advance the quest to find a successful treatment for Alzheimer's disease. We would like to acknowledge the dedication of all the participants, the site personnel, and all of the partnership team members who continue to make the A4 and LEARN Studies possible. The complete A4 Study Team list is available on: a4study.org/a4-study-team.; the Adult Changes in Thought study (ACT), U01 AG006781, U19 AG066567; Alzheimer's Disease Neuroimaging Initiative (ADNI): Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California; Estudio Familiar de Influencia Genetica en Alzheimer (EFIGA): 5R37AG015473, RF1AG015473, R56AG051876; Memory & Aging Project at Knight Alzheimer's Disease Research Center (MAP at Knight ADRC): The Memory and Aging Project at the Knight-ADRC (Knight-ADRC). This work was supported by the National Institutes of Health (NIH) grants R01AG064614, R01AG044546, RF1AG053303, RF1AG058501, U01AG058922 and R01AG064877 to Carlos Cruchaga. The recruitment and clinical characterization of research participants at Washington University was supported by NIH

grants P30AG066444, P01AG03991, and P01AG026276. Data collection and sharing for this project was supported by NIH grants RF1AG054080, P30AG066462, R01AG064614 and U01AG052410. We thank the contributors who collected samples used in this study, as well as patients and their families, whose help and participation made this work possible. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, the Neurogenomics and Informatics Center (NGI: <https://neurogenomics.wustl.edu/>) and the Departments of Neurology and Psychiatry at Washington University School of Medicine; National Alzheimer's Coordinating Center (NACC): The NACC database is funded by NIA/NIH Grant U24 AG072122. NACC data are contributed by the NIA-funded ADRCs: P30 AG062429 (PI James Brewer, MD, PhD), P30 AG066468 (PI Oscar Lopez, MD), P30 AG062421 (PI Bradley Hyman, MD, PhD), P30 AG066509 (PI Thomas Grabowski, MD), P30 AG066514 (PI Mary Sano, PhD), P30 AG066530 (PI Helena Chui, MD), P30 AG066507 (PI Marilyn Albert, PhD), P30 AG066444 (PI John Morris, MD), P30 AG066518 (PI Jeffrey Kaye, MD), P30 AG066512 (PI Thomas Wisniewski, MD), P30 AG066462 (PI Scott Small, MD), P30 AG072979 (PI David Wolk, MD), P30 AG072972 (PI Charles DeCarli, MD), P30 AG072976 (PI Andrew Saykin, PsyD), P30 AG072975 (PI David Bennett, MD), P30 AG072978 (PI Neil Kowall, MD), P30 AG072977 (PI Robert Vassar, PhD), P30 AG066519 (PI Frank LaFerla, PhD), P30 AG062677 (PI Ronald Petersen, MD, PhD), P30 AG079280 (PI Eric Reiman, MD), P30 AG062422 (PI Gil Rabinovici, MD), P30 AG066511 (PI Allan Levey, MD, PhD), P30 AG072946 (PI Linda Van Eldik, PhD), P30 AG062715 (PI Sanjay Asthana, MD, FRCP), P30 AG072973 (PI Russell Swerdlow, MD), P30 AG066506 (PI Todd Golde, MD, PhD), P30 AG066508 (PI Stephen Strittmatter, MD, PhD), P30 AG066515 (PI Victor Henderson, MD, MS), P30 AG072947 (PI Suzanne Craft, PhD), P30 AG072931 (PI Henry Paulson, MD, PhD), P30 AG066546 (PI Sudha Seshadri, MD), P20 AG068024 (PI Erik Roberson, MD, PhD), P20 AG068053 (PI Justin Miller, PhD), P20 AG068077 (PI Gary Rosenberg, MD), P20 AG068082 (PI Angela Jefferson, PhD), P30 AG072958 (PI Heather Whitson, MD), P30 AG072959 (PI James Leverenz, MD); National Institute on Aging Alzheimer's Disease Family Based Study (NIA-AD FBS): U24 AG056270; Religious Orders Study (ROS): P30AG10161, R01AG15819, R01AG42210; Memory and Aging Project (MAP - Rush): R01AG017917, R01AG42210; Minority Aging Research Study (MARS): R01AG22018, R01AG42210; Washington Heights/Inwood Columbia Aging Project (WHICAP): RF1 AG054023; and Wisconsin Registry

for Alzheimer's Prevention (WRAP): R01AG027161 and R01AG054047. Additional acknowledgments include the National Institute on Aging Genetics of Alzheimer's Disease Data Storage Site (NIAGADS, U24AG041689) at the University of Pennsylvania, funded by NIA.